RxDoctor Payments Data

Nora McNamara

Child & Adolescent Psychiatry · Cleveland, OHNPI 1871513127

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,588 of the $3,196 with a category attached, or 81.0%. 7 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 56.6% of the total. Reporting peaked in 2019 at $3,104 and has fallen 97.5% since, to $77 in 2022. Among child & adolescent psychiatry clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,196in general payments, 2019–2025

Across 17 payments — averaging $188.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$2K
  • Roche Products Limited$1K
  • Shire North American Group Inc$90
  • Johnson & Johnson$48
  • Indivior Inc.$15
  • Takeda Pharmaceuticals U.S.A., Inc.$15
  • plus $14 from 1 others
$568,494in research payments, 2019–2025

Across 112 payments — averaging $5075.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$205K
  • F. Hoffmann-la Roche AG$195K
  • Hoffmann-la Roche Limited$68K
  • Sunovion Pharmaceuticals Inc.$63K
  • AbbVie$13K
  • Pfizer$6K
  • plus $17K from 5 others

What the payments were for

  • Travel & lodging$2,58881%
  • Food & beverage$60919%

General payments by program year

19
20
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,196 in reported general payments places this provider in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.

See all child & adolescent psychiatry providers in Ohio

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate54$161,575
Abilify MaintenaAripiprazole14$32,623
Clozapine89$4,721
Chlorpromazine Hcl12$3,556
Paliperidone ErPaliperidone33$2,183
Quetiapine Fumarate36$1,411
Fluphenazine Hcl13$1,112
Divalproex Sodium24$933
Haloperidol Decanoate12$863
Olanzapine52$840
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$778
Haloperidol17$763
Ziprasidone Hcl17$650
Trazodone Hcl25$619
Benztropine Mesylate69$528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$48$161,57554 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 160 child & adolescent psychiatry providers in Ohio.

Other child & adolescent psychiatry in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →